ISSN 1725-2423

Official Journal

of the European Union

C 18
European flag  

English edition

Information and Notices

Volume 50
26 January 2007

Notice No

Contents

page

 

IV   Notices

 

NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES

 

Commission

2007/C 018/01

Euro exchange rates

1

2007/C 018/02

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2006 to 31 December 2006(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

2

2007/C 018/03

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2006 to 31 December 2006(Decisions taken pursuant to Article 34 of Directive 2001/83/EC or Article 38 of Directive 2001/82/EC)

4

 

V   Announcements

 

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMMON COMMERCIAL AND COMPETITION POLICY

 

Commission

2007/C 018/04

Prior notification of a concentration (Case COMP/M.4558 — Alpha Private Equity Funds/Non Ferrous International Group) — Candidate case for simplified procedure ( 1 )

13

2007/C 018/05

Prior notification of a concentration (Case COMP/M.4460 — ABN AMRO/Carlson/T.G.I. Friday's) — Candidate case for simplified procedure ( 1 )

14

 

 

(1)   Text with EEA relevance

EN

 

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Commission

26.1.2007   

EN

Official Journal of the European Union

C 18/1

Euro exchange rates (1)

25 January 2007

(2007/C 18/01)

1 euro=

 

Currency

Exchange rate

USD

US dollar

1,2978

JPY

Japanese yen

156,88

DKK

Danish krone

7,4541

GBP

Pound sterling

0,65850

SEK

Swedish krona

9,0750

CHF

Swiss franc

1,6154

ISK

Iceland króna

89,12

NOK

Norwegian krone

8,2120

BGN

Bulgarian lev

1,9558

CYP

Cyprus pound

0,5784

CZK

Czech koruna

28,148

EEK

Estonian kroon

15,6466

HUF

Hungarian forint

254,65

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,6975

MTL

Maltese lira

0,4293

PLN

Polish zloty

3,8975

RON

Romanian leu

3,3926

SKK

Slovak koruna

35,178

TRY

Turkish lira

1,8403

AUD

Australian dollar

1,6639

CAD

Canadian dollar

1,5287

HKD

Hong Kong dollar

10,1308

NZD

New Zealand dollar

1,8468

SGD

Singapore dollar

1,9929

KRW

South Korean won

1 214,81

ZAR

South African rand

9,3114

CNY

Chinese yuan renminbi

10,0846

HRK

Croatian kuna

7,3800

IDR

Indonesian rupiah

11 803,49

MYR

Malaysian ringgit

4,5429

PHP

Philippine peso

63,469

RUB

Russian rouble

34,3940

THB

Thai baht

44,320

(1)  

Source: reference exchange rate published by the ECB.

26.1.2007   

EN

Official Journal of the European Union

C 18/2

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2006 to 31 December 2006

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1))

(2007/C 18/02)

—   Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

4.12.2006

Naglazyme

BioMarin Europe Limited

Axtell House

23-24 Warwick Street

London W1B 5NQ

United Kingdom

EU/1/05/324/001

6.12.2006

4.12.2006

Kaletra

Abbott Laboratories Ltd

Queenborough

Kent ME11 5EL

EU/1/01/172/001-005

8.12.2006

11.12.2006

Rotarix

GlaxoSmithKline Biologicals s.a.

rue de l'Institut 89

B-1330 Rixensart

EU/1/05/330/001-004

13.12.2006

18.12.2006

NeoSpect

CIS bio international

Route Nationale 306

Saclay

Boîte Postale 32

F-91192 Gif-sur-Yvette

EU/1/00/154/001-002

21.12.2006

18.12.2006

Viracept

Roche Registration Limited

6 Falcon Way

Shire Park

Welwyn Garden City

AL7 1TW

United Kingdom

EU/1/97/054/003-004

EU/1/97/054/006

20.12.2006

18.12.2006

ATryn

LEO Pharma A/S

Industriparken 55

DK-2750 Ballerup

Genzyme Europe B.V.

Gooimeer 10

1411 DD Naarden

Nederland

EU/1/06/355/001-003

20.12.2006

19.12.2006

SonoVue

Bracco International B.V.

Strawinskylaan 3051

1077ZX Amsterdam

Nederland

EU/1/01/177/001

21.12.2006

—   Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision

Name of the medicinal product

INN

(International Non-Proprietary Name)

Holder of the marketing authorization

Number of the entry in the Community Register

Pharmaceutical form

ATC code

(Anatomical Therapeutic Chemical Code)

Date of notification

18.12.2006

PRAC-TIC

pyriprole

Novartis Sanidad Animal S.L.

Calle de la Marina, 206

E-08013 Barcelona

EU/2/06/066/001-012

Spot-on solution

QP53AX26

20.12.2006

20.12.2006

Medicinal Oxygen Air Liquide Santé

Oxygen

Air Liquide Santé International

10 rue Cognacq-Jay

F-75341 Paris Cedex 07

EU/2/06/067/001-002

Inhalation gas

QV03AN01

22.12.2006

19.12.2006

ProMeris

Metaflumizone

Fort Dodge Animal Health Holland

C.J. van Houtenlaan 36

1381 CP Weesp

Nederland

EU/2/06/064/001-004

Spot-on solution

QP 53AX25

22.12.2006

19.12.2006

ProMeris Duo

Metaflumizone, Amitraz

Fort Dodge Animal Health Holland

C.J. van Houtenlaan 36

1381 CP Weesp

Nederland

EU/2/06/065/001-010

Spot-on solution

QP 53AD51

21.12.2006

—   Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Rejected

Date of the decision

Name of the medicinal product

Holder of the marketing authorization

Number of the entry in the Community Register

Date of notification

11.12.2006

Veraflox

Bayer HealthCare AG

D-51368 Leverkusen

-

14.12.2006

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency

7, Westferry Circus, Canary Wharf

London E14 4HB

United Kingdom

(1)  OJ L 136 of 30.4.2004, p. 1.

26.1.2007   

EN

Official Journal of the European Union

C 18/4

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2006 to 31 December 2006

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC (1) or Article 38 of Directive 2001/82/EC (2))

(2007/C 18/03)

—   Issuing, maintenance or modification of a national marketing authorisation

Date of the decision

Name(s) of the medicinal product

Holder(s) of the marketing authorization

Member State concerned

Date of notification

13.12.2006

Glucomed

See Annex I

See Annex I

14.12.2006

13.12.2006

Agopton

See Annex II

See Annex II

14.12.2006

—   Suspension of a national marketing authorization

Date of the decision

Name(s) of the medicinal product

Holder(s) of the marketing authorization

Member State concerned

Date of notification

19.12.2006

Cetirizine Nordic Drugs

See Annex III

See Annex III

21.12.2006

19.12.2006

Cetirizine Dermapharm

See Annex IV

See Annex IV

21.12.2006

19.12.2006

Cetirizine Apex

See Annex V

See Annex V

21.12.2006

(1)  OJ L 311, 28.11.2001, p. 67.

(2)  OJ L 311, 28.11.2001, p. 1.

ANNEX I

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANT, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES

Member State

Marketing Authorisation Holder

Applicant

Invented name

Strength

Pharmaceutical Form

Route of administration

Austria

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Flexove

625 mg

Tablet

Oral use

Belgium

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Flexove

625 mg

Tablet

Oral use

Cyprus

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Czech Republic

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Flexove

625 mg

Tablet

Oral use

Denmark

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Estonia

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Finland

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

France

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Germany

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Greece

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Hungary

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Flexove

625 mg

Tablet

Oral use

Ireland

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Flexove

625 mg

Tablet

Oral use

Italy

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Latvia

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Lithuania

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Luxemburg

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

The Netherlands

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Poland

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Portugal

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Slovakia

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Spain

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Sweden

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

United Kingdom

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Iceland

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Glucomed

625 mg

Tablet

Oral use

Norway

—

Navamedic ASA

Vollsveien 13 C

N-1327 Lysaker

Flexove

625 mg

Tablet

Oral use

ANNEX II

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State

Marketing Authorisation Holder

Product name

Strength

Pharmaceutical form

Route of administration

Austria

Takeda Pharma Ges.m.b.H.

Seidengasse 33-35

A-1070 Vienna

AGOPTON

15 mg

Capsule

Oral use

AGOPTON

30 mg

Capsule

Oral use

AGOPTON Rapid

15 mg

Oro-dispersible tablet

Oral use

AGOPTON Rapid

30 mg

Oro-dispersible tablet

Oral use

Belgium

Sanofi-Synthelabo SA NV

Dobbelenberg

5, Avenue de la Metrologie

B-1130 Brussels

DAKAR

15mg

Capsule

Oral use

DAKAR

30 mg

Capsule

Oral use

NIBITOR

30 mg

Capsule

Oral use

Denmark

Wyeth ab

Box 1822

S-171 24 Solna

LANZO

15 mg

Capsule

Oral use

LANZO

30 mg

Capsule

Oral use

Finland

Wyeth AB

Box 1822

S-171 24 Solna

LANZO

30 mg

Capsule

Oral use

LANZO

15 mg

Oro-dispersible tablet

Oral use

LANZO

30 mg

Oro-dispersible tablet

Oral use

France

Laboratoires Takeda SA

15, quai de Dion Bouton

F-92816 Puteaux Cedex

OGAST

15 mg

Capsule

Oral use

OGAST

30 mg

Capsule

Oral use

Sanofi-Aventis

46 quai de la Râpée

F-75601 Paris Cedex 12

LANZOR

15 mg

Capsule

Oral use

LANZOR

30 mg

Capsule

Oral use

Germany

Takeda Pharma GmbH

Viktoriaallee 3-5

D-52066 Aachen

AGOPTON

15 mg

Capsule

Oral use

AGOPTON

30 mg

Capsule

Oral use

LANZOR

15 mg

Capsule

Oral use

LANZOR

30 mg

Capsule

Oral use

Greece

Vianex S.A.

Tatoiou Street

EL-146 71 Nea Erythrea, Athens

LAPRAZOL

15 mg

Capsule

Oral use

LAPRAZOL

30 mg

Capsule

Oral use

LAPRAZOL FasTab

15 mg

Oro-dispersible tablet

Oral use

LAPRAZOL FasTab

30 mg

Oro-dispersible tablet

Oral use

Hungary

Gedeon Richter

Gyomrói út 19-21

H-1103 Budapest

LANSONE

30 mg

Capsule

Oral use

Ireland

John Wyeth & Brother Limited

Trading as Wyeth Pharmaceuticals

Huntercombe Lane South

Taplow, Maidenhead

Berkshire SL6 0PH

United Kingdom

ZOTON

15 mg

Capsule

Oral use

ZOTON

30 mg

Capsule

Oral use

ZOTON FasTab

15 mg

Oro-dispersible tablet

Oral use

ZOTON FasTab

30 mg

Oro-dispersible tablet

Oral use

Cyanamid of Great Briain Ltd.

Fareham Road

GOSPORT Hampshire PO13 0AS

United Kingdom

ZOTON

30mg

Gastro-resistant granules for oral suspension

Oral use

Italy

Takeda Italia Farmaceutici S.p.A.

Via Elio Vittorini 129

I-00144 Roma

LANSOX

15 mg

Capsule

Oral use

LANSOX

30 mg

Capsule

Oral use

LANGAST

15 mg

Capsule

Oral use

LANGAST

30 mg

Capsule

Oral use

LANSOX

15 mg

Oro-dispersible tablet

Oral use

LANSOX

30 mg

Oro-dispersible tablet

Oral use

Sigma-Tau S.p.A.

Via Pontina km. 30,400

I-00040 Pomezia, Roma

LIMPIDEX

15 mg

Capsule

Oral use

LIMPIDEX

30 mg

Capsule

Oral use

LIMPIDEX

15 mg

Oro-dispersible tablet

Oral use

LIMPIDEX

30 mg

Oro-dispersible tablet

Oral use

Wyeth Lederle S.p.A.

Via Nettunense, 90

I-04011 Aprilia (LT)

ZOTON

15 mg

Capsule

Oral use

ZOTON

30 mg

Capsule

Oral use

ZOTON

15 mg

Oro-dispersible tablet

Oral use

ZOTON

30 mg

Oro-dispersible tablet

Oral use

Luxembourg

Sanofi-Synthelabo SA NV

Dobbelenberg, 5, Avenue de la Metrologie

B-1130 Brussels

DAKAR

15 mg

Capsule

Oral use

DAKAR

30 mg

Capsule

Oral use

Netherlands

Sanofi-Synthelabo B.V./Aventis Pharma B.V.

Kampenringweg 45 D-E (toren D en E)

2803 PE Gouda

Nederland

PREZAL

15 mg

Capsule

Oral use

PREZAL

30 mg

Capsule

Oral use

Portugal

Seber Portuguesa Farmacêutica, SA

Rua Norberto de Oliveira, 1 a 5

P-2620-111 Póvoa de Santo Adrião

OGASTO

15 mg

Capsule

Oral use

OGASTO

30 mg

Capsule

Oral use

OGASTO

15 mg

Oro-dispersible tablet

Oral use

OGASTO

30 mg

Oro-dispersible tablet

Oral use

Spain

Almirall Prodesfarma, S.A.

General Mitre, 151

E-08022 Barcelona

OPIREN

15 mg

Capsule

Oral use

OPIREN

30 mg

Capsule

Oral use

BAMALITE

15 mg

Capsule

Oral use

BAMALITE

30 mg

Capsule

Oral use

OPIREN Flas

15 mg

Oro-dispersible tablet

Oral use

OPIREN Flas

30 mg

Oro-dispersible tablet

Oral use

BAMALITE Flas

15 mg

Oro-dispersible tablet

Oral use

BAMALITE Flas

30 mg

Oro-dispersible tablet

Oral use

Sweden

Wyeth AB

Box 1822

S-171 24 Solna

LANZO

15 mg

Capsule

Oral use

LANZO

30 mg

Capsule

Oral use

LANZO

15 mg

Oro-dispersible tablet

Oral use

LANZO

30 mg

Oro-dispersible tablet

Oral use

United Kingdom

John Wyeth & Brother Limited

Trading as Wyeth Pharmaceuticals

Huntercombe Lane South

Taplow, Maidenhead

Berkshire SL6 0PH

United Kingdom

ZOTON

15 mg

Capsule

Oral use

ZOTON

30 mg

Capsule

Oral use

ZOTON

30 mg

Gastro-resistant granules for oral suspension

Oral use

ZOTON FasTab

15 mg

Oro-dispersible Tablet

Oral use

ZOTON FasTab

30 mg

Oro-dispersible Tablet

Oral use

Iceland

Wyeth AB

Box 1822

S-171 24 Solna

LANZO

15 mg

Capsule

Oral use

LANZO

30 mg

Capsule

Oral use

ZOTON

15 mg

Capsule

Oral use

ZOTON

30 mg

Capsule

Oral use

LANZO

15 mg

Oro-dispersible tablet

Oral use

LANZO

30 mg

Oro-dispersible tablet

Oral use

Norway

Wyeth AB

Box 1822

S-171 24 Solna

LANZO

15 mg

Capsule

Oral use

LANZO

30 mg

Capsule

Oral use

LANZO

15 mg

Oro-dispersible tablet

Oral use

LANZO

30 mg

Oro-dispersible tablet

Oral use

ANNEX III

LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

CETIRIZINE DIHYDROCHLORIDE NORDIC DRUGS 10 mg AND ASSOCIATED NAMES

Member State

Marketing Authorisation Holder

Product Name

Strength

Pharmaceutical Form

Route of administration

Denmark

Nordic Drugs AB

Geijersgatan 4 C

S-200 61 Limhamn

Gardex

10 mg

Film coated tablet

Oral

Finland

Nordic Drugs AB

Geijersgatan 2A

Box 30035

S-200 61 Limhamn

Gardex 10 mg tabletti, kalvopäällysteinen

10 mg

Film coated tablet

Oral

Netherlands

Nordic Drugs AB

Box 30035

S-200 61 Limhamn

Cetirizine dihydrochloride Nordic Drugs 10 mg

10 mg

Film coated tablet

Oral

Norway

Nordic Drugs AB,

Box 30035

S-200 61 Limhamn

Acura

10 mg

Film coated tablet

Oral

Sweden

Nordic Drugs AB

Box 300 35

S-200 61 Limhamn

Acura

10 mg

Film coated tablet

Oral

ANNEX IV

LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

CETIRIZINE DIHYDROCHLORIDE DERMAPHARM 10 mg AND ASSOCIATED NAMES

Member State

Marketing Authorisation Holder

Product Name

Strength

Pharmaceutical Form

Route of administration

Austria

Dermapharm GmbH

Türkenstr. 25/12

A-1090 Wien

Cetiderm 10 mg Filmtabletten

10 mg

Film coated tablet

Oral

Belgium

Dermapharm AG

Luise-Ullrich-Str. 6

D-82031 Grünwald

Cetirizine dihydrochloride Dermapharm 10 mg filmomhulde tabletten

10 mg

Film coated tablet

Oral

Germany

Dermapharm AG

Luise-Ullrich-Str. 6

D-82031 Grünwald

Cetiderm 10 mg Filmtabletten

10 mg

Film coated tablet

Oral

Netherlands

Dermapharm AG

Luise-Ullrich-Str. 6

D-82031 Grünwald

Cetirizine dihydrochloride Dermapharm 10 mg tabletten

10 mg

Film coated tablet

Oral

ANNEX V

LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

CETIRIZINE DIHYDROCHLORIDE APEX 10 mg AND ASSOCIATED NAMES

Member State

Marketing Authorisation Holder

Product Name

Strength

Pharmaceutical Form

Route of administration

Belgium

Docpharma N.V.

Ambachtenlaan 13 H

B-3001 Heverlee

Doccetiri

10 mg

Film coated tablet

Oral

Luxembourg

Docpharma N.V.

Ambachtenlaan 13 H

B-3001 Heverlee

Doccetiri-10

10 mg

Film coated tablet

Oral

Netherlands

Apex Pharmaceuticals Ltd.

2nd Floor, Devlin House

36 Saint George Street

Mayfair

W1S 2FW London

United Kingdom

Cetirizine dihydrochloride-APEX 10 mg

10 mg

Film coated tablet

Oral

V Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMMON COMMERCIAL AND COMPETITION POLICY

Commission

26.1.2007   

EN

Official Journal of the European Union

C 18/13

Prior notification of a concentration

(Case COMP/M.4558 — Alpha Private Equity Funds/Non Ferrous International Group)

Candidate case for simplified procedure

(Text with EEA relevance)

(2007/C 18/04)

1.

On 19 January 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Alpha Private Equity Funds (Channel Islands) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of Non Ferrous International Group consisting of Non Ferrous International NV/SA (Belgium) and DI Assets S.A. (Luxembourg), by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

—

for Alpha Private Equity Funds: private equity investments;

—

for Non Ferrous International Group: trade of electric, electronic, ferrous and non-ferrous scrap; and production and sale of non-ferrous metals.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4558 — Alpha Private Equity Funds/Non Ferrous International Group, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Bruxelles/Brussel

(1)  OJ L 24, 29.1.2004, p. 1.

(2)  OJ C 56, 5.3.2005, p. 32.

26.1.2007   

EN

Official Journal of the European Union

C 18/14

Prior notification of a concentration

(Case COMP/M.4460 — ABN AMRO/Carlson/T.G.I. Friday's)

Candidate case for simplified procedure

(Text with EEA relevance)

(2007/C 18/05)

1.

On 18 January 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings ABN AMRO Capital BO Funds B.V. (‘AACBOF’, the Netherlands) belonging to the ABN AMRO group and Carlson Restaurants Worldwide Inc., a wholly owned subsidiary of Carlson Companies Inc. (‘Carlson’ USA) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of the UK T.G.I. Friday's franchised restaurant business of Whitbread Group Plc. (‘Whitbread’, UK) by way of purchase of shares in a newly created company constituting a joint venture.

2.

The business activities of the undertakings concerned are:

—

for undertaking ABN AMRO: provider of banking and financial services;

—

for undertaking Carlson: active in the marketing, travel and hospitality sector;

—

for T.G.I. Friday's restaurant: informal restaurants.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4460 — ABN AMRO/Carlson/T.G.I. Friday's, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Bruxelles/Brussel

(1)  OJ L 24, 29.1.2004, p. 1.

(2)  OJ C 56, 5.3.2005, p. 32.